Global Coalition for Adaptive Research @GCAResearch

GCAR’s CEO/President, Meredith Buxton, and Chief Business and Strategy Officer, Rob Murray, catching up with Diane Simeone @MadameSurgeon, member of the IMPACT PDAC leadership council at #ASCO26. IMPACT PDAC (Innovative Master Protocol to Accelerate Clinical Therapeutics for Pancreatic Ductal Adenocarcinoma) is the next phase in a groundbreaking effort to advance new treatments for pancreatic cancer. This new master protocol is sponsored by GCAR and builds on a strategic alliance with @PanCAN . To learn more about this forthcoming, groundbreaking trial, visit: gcaresearch.org/research/impac…

We’re honored to partner with the @CCAlliance to launch KLEOS - a ground-breaking step toward changing how colorectal cancer therapies are developed and evaluated. By combining the Alliance’s leadership and compassion with GCAR’s expertise in adaptive platform trials, we’re building a more efficient, collaborative, and truly patient-centered path to discovery. This work can accelerate learning, reduce barriers, and bring promising treatments to patients sooner. We’re deeply grateful to the patients, advocates, clinicians, and researchers making this possible. Excited and inspired by what lies ahead! #KLEOS #ColorectalCancer #ClinicalTrial #AccelerateLearning

Colorectal Cancer Alliance @CCAlliance

6 days ago

If you or someone you love has colorectal cancer, you know the hardest part isn't just the diagnosis — it's the waiting. Waiting for new treatments that take too long. Waiting for something better. Today at the Annual Meeting of the American Society of Clinical Oncology, we're

0 7 13 1K 0

The newly seated Project Cure CRC Consortium, assembled to guide the Alliance's work toward cures, got its first look at KLEOS at the ASCO annual meeting in Chicago. The Alliance's adaptive clinical trial platform was the focus of a panel featuring Alliance CEO Michael Sapienza and Dr. Meredith Buxton, CEO of the Global Coalition for Adaptive Research, among other oncology leaders. Panelists discussed KLEOS's vast potential and urgent goal to bring new treatments to patients faster. Learn more about KLEOS: bit.ly/KLEOS-Announce… #ASCO26 @ASCO

keyboard_arrow_left Previous keyboard_arrow_right Next

May is Neurofibromatosis Awareness Month. Advancing therapies for rare diseases like NF requires bold new approaches. GCAR, with the @ChildrensTumor Foundation, is powering a first‑of‑its‑kind adaptive platform trial to efficiently evaluate investigational therapies across key NF1 manifestations. For pharma and biotech partners, this model streamlines evidence generation, shortens development timelines, and speeds critical decisions - bringing potential treatments to patients faster. Join us in accelerating progress for people with NF. Email [email protected] to learn more. #NeurofibromatosisAwarenessMonth #NFawareness #EndNF #Neurofibromatosis #NF1 #NFResearch

Want a smarter, faster path for your oncology asset? Explore GCAR’s cutting-edge master protocols across glioblastoma, pancreatic, biliary tract, and ovarian cancers. Connect with our team at #ASCO2026 📩 Email us to schedule a meeting – [email protected] #ClinicalResearch #ClinicalTrials #PlatformTrials #MasterProtocol #AdaptiveTrials

GCAR is accelerating a portfolio of collaborative master protocols across glioblastoma, pancreatic, biliary tract, and ovarian cancers. Our adaptive platforms speed evaluation of promising therapies. Have an oncology asset? Let’s connect at #ASCO26 to explore platform trial opportunities. 📩 Email us to schedule a meeting – [email protected] #ClinicalResearch #ClinicalTrials #PlatformTrials #Adaptive #Oncology

Today, on International Clinical Trials Day, we recognize that clinical research is a truly global endeavor. Progress in medicine depends on collaboration - bringing together patients, investigators, institutions, industry partners, and advocates from around the world with a shared commitment to advancing science and improving lives. At GCAR, we are proud to contribute to multinational partnerships and global learning networks that accelerate research, expand access to innovation, and generate knowledge that benefits patients everywhere. Thank you to every patient, caregiver, researcher, clinician, coordinator, and partner helping move clinical research forward together. #InternationalClinicalTrialsDay #ClinicalResearch #GlobalCollaboration #Innovation #ClinicalTrials

We had the privilege of welcoming @melinda_bachini, Chief Patient Officer of the Cholangiocarcinoma Foundation @curecc, to speak with our team about her passion for patient advocacy. Drawing on her personal experience, she offers valuable insight into the patient viewpoint in clinical trials. A 16-year survivor of cholangiocarcinoma, Melinda shared powerful perspectives that serve as an important reminder of the real-world impact of clinical research - and the patients at the center of it. Through our collaboration with the Cholangiocarcinoma Foundation and disease experts, we are developing ARBOR BTC, an innovative platform trial to advance new options for patients with biliary tract cancer. At GCAR, we are committed to making clinical trials more efficient and accelerating the discovery and development of new therapies. We’re deeply grateful to Melinda for sharing her story and for her continued leadership in the patient advocacy community. 💚

Tomorrow is International Clinical Trials Day – a day to recognize the vital role of clinical research in advancing new treatment options for patients. At GCAR, we are proud to be pioneering progress through a portfolio of innovative platform trials across glioblastoma, posttraumatic stress disorder, ovarian cancer, biliary tract cancer, neurofibromatosis, and pancreatic cancer - working to evaluate therapies more efficiently and expand access to promising options. Together with our partners, we’re helping shape a more collaborative, patient-centered future for clinical trials. #CTD2026 #ClinicalTrialsDay #FasterTogether

The “GCAR Glioma Getters” Team joined the National Brain Tumor Society’s Brain Tumor Walk & Race in Los Angeles, while GCAR staff, family, and friends across the country participated remotely to show nationwide support. 🧠🙌 GCAR was proud to participate; Rachel Rosenstein‑Sisson spoke at the Southern California event alongside patients, caregivers, advocates, and supporters united in advancing progress for those affected by brain tumors. Thank you to NBTS for an inspiring, meaningful day. Together we’ll keep pushing for better treatments and brighter futures. @NBTStweets #BrainTumorAwareness #GoGrayInMay #Glioblastoma #GBMAGILE #ClinicalResearch #FasterTogether

PTSD can develop after many types of trauma, and it doesn’t look the same for everyone. While effective therapies exist, research shows that many military members and veterans do not experience enough relief from currently available treatment options. The M‑PACT trial was launched to address this gap - establishing a trial framework that can evaluate multiple investigational treatments at once - so progress can happen faster. Learn more: ptsdclinicaltrial.org #MentalHealthAwarenessMonth #MentalHealthIsHealth #PTSDresearch #ClinicalResearch #MentalHealthMatters #ResearchMatters #PTSD #ClinicalTrial

On World Ovarian Cancer Day, we recognize the urgent need to advance new treatment options for patients. GCAR is advancing two innovative clinical trial initiatives: • Ovarian CanceRx – a biomarker-driven platform designed to efficiently evaluate promising therapies for high-grade ovarian cancer • Low-Grade Serous Ovarian Cancer Platform Trial – an adaptive framework focused on accelerating options for patients with LGSOC We welcome conversations with pharma and biotech teams exploring development pathways for investigational therapies targeting #OvarianCancer. Email us at [email protected] #WorldOvarianCancerDay #OvarianCancer #OvarianCancerAwareness #ClinicalTrials #ResearchMatters #HopeThroughResearch

May is Mental Health Awareness Month 💚 Millions of people live with mental health conditions, including PTSD - and many are seeking more effective treatment options. This month, we’re highlighting the importance of the M-PACT study (Military and Veterans PTSD Adaptive Platform Clinical Trial) to help advance new, evidence‑based PTSD treatments through research. To learn more about this study, visit: ptsdclinicaltrial.org #MentalHealthAwarenessMonth #MentalHealthIsHealth #PTSDresearch #ClinicalResearch #MentalHealthMatters #ResearchMatters #PTSD #ClinicalTrial

Across the country, GCAR staff, family, and friends came together for #PurpleStride in support of @PanCAN and the #PancreaticCancer community. 💜 We’re proud to partner with PanCAN and pancreatic cancer experts to accelerate the evaluation of new treatment options for pancreatic cancer. Learn more about the forthcoming IMPACT PDAC clinical trial: gcaresearch.org/research/impac…

May is NF Awareness Month - a time to raise awareness of #Neurofibromatosis and the need for better treatment options. GCAR is supporting the Children's Tumor Foundation @ChildrensTumor and NF experts to advance an innovative platform trial designed to evaluate multiple therapies more efficiently and identify new options for patients. To learn more about the Neurofibromatosis Platform Trial, visit: gcaresearch.org/research/neuro… #NFAwarenessMonth #Neurofibromatosis #ClinicalTrials #ResearchMatters #UnmetNeed

May is Brain Tumor Awareness Month – a month to raise awareness and highlight the progress of #GBMAGILE, an innovative clinical trial for individuals diagnosed with #glioblastoma. GBM AGILE enables multiple drugs (and combinations of drugs) to be screened simultaneously and over time, revolutionizing the way new therapies are developed. 📣 Recent trial news: > Tinostamustine is now enrolling and will recruit across multiple international trial sites! View the announcement: gcaresearch.org/news/gcar-and-… > Publication of regorafenib trial results Read the full article in the Journal of Clinical Oncology @JCO_ASCO: ascopubs.org/doi/10.1200/JC… To learn more about this innovative trial, visit: gcaresearch.org #GrayMay #GoGrayInMay #BrainTumorAwarenessMonth #BTAM #GBMAGILE

We’re looking forward to participating in the National Brain Tumor Society’s Southern California Brain Tumor Walk on Saturday, May 9th! As a key advocacy partner, the National Brain Tumor Society @NBTStweets collaborates with GCAR on GBM AGILE - a patient-centric, adaptive platform trial advancing the fight against brain cancer. Have questions about #GBMAGILE or want to share your experience? We’d love to connect. Stop by our tent for coffee and bagels 🥯☕ we’ll be there for conversation and to answer your questions. To learn more about this event, visit: braintumor.org/event/southern… #GoGrayInMay

NEW Publication - Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial Read the full article in Journal of Clinical Oncology: ascopubs.org/doi/10.1200/JC… #GBMAGILE #glioblastoma #GBM #Bayesian #PlatformTrial

Great to be at AACR connecting with clinical leaders who are collaborating with GCAR to advance innovative clinical trials across multiple cancers. Collaboration like this is key to moving research forward and bringing new treatment options to patients. Photos: GCAR’s Meredith Buxton and Rob Murray with Drs. @DrMhidalgo, @MadameSurgeon, @AnilSoodMD, Funda Meric-Bernstam, Rachel Grisham, and Charlie Gourley. #AACR2026